(Q64121003)

English

Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Aggressive B-Cell Lymphoma

clinical trial

In more languages

default values for all languages

No label defined

No description defined

edit

Statements

instance of

clinical trial

0 references

title

Rituximab, Bendamustine and Lenalidomide in Patients With Aggressive B-cell Lymphoma Not Eligible for High Dose Chemotherapy or Anthracycline-Based Therapy. A Phase I/II Trial. (English)

0 references

0 references

0 references

September 2009

0 references

end time

April 2014

0 references

number of participants

49

0 references

research intervention

rituximab

0 references

(RS)-lenalidomide

0 references

bendamustine hydrochloride

0 references

clinical trial phase

phase I clinical trial

0 references

phase II clinical trial

0 references

research site

Kantonsspital Baden

0 references

Kantonsspital St. Gallen

0 references

minimum age

18 year

0 references

study type

interventional study

0 references

stated in

Rituximab, bendamustine and lenalidomide in patients with aggressive B-cell lymphoma not eligible for anthracycline-based therapy or intensive salvage chemotherapy - SAKK 38/08.

0 references

Rituximab, bendamustine, and lenalidomide in patients with aggressive B cell lymphoma not eligible for high-dose chemotherapy or anthracycline-based therapy: phase I results of the SAKK 38/08 trial

0 references

Identifiers

ClinicalTrials.gov ID

NCT00987493

0 references

(Q64121003)

Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Aggressive B-Cell Lymphoma

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)